Three $10k prizes for initiatives that improve access / create demand for diagnostics in LMICs

Dear All:

Following the precept (often attributed to Osler, but I can’t find it in his Principles and Practice 1892) that the 3 core elements of treatment are “diagnosis, diagnosis, and diagnosis,” FIND (Foundation for Innovative New Diagnostics) is an international non-profit organization that enables the development and delivery of diagnostic tests for poverty-related diseases, including TB, malaria, HIV/AIDS, sleeping sickness, HCV, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola.

FIND have now established “Voices for Diagnosis,” a new annual prize to recognize individuals and organizations who are implementing innovative approaches that will improve access and create demand for timely, cost-effective diagnostic solutions for infectious diseases in low- and middle-income countries.

For 2018/19, three prizes of $10k will be awarded. The theme is “Get rational: protecting antibiotics by promoting approaches that support evidence-based prescribing.” The prizes are being contributed by FIND itself, BD, and Johnson & Johnson.

The focus for the first 3 prizes is on innovative approaches to decrease the inappropriate prescription of antibiotics through better diagnostic solutions. Does this match the work you’re doing? If so, find out more and apply here before 31 March 2019: http://www.finddx.org/voices

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

  • 29-30 Nov 2018 (Birmingham, UK): BSAC (British Society Antimicrobial Chemotherapy): Antibiotic Resistance Mechanisms Workshop for Researchers
  • 7 Dec 2018 (Boston, MA): BAARN, Boston Area Antimicrobial Resistance Network 2018 symposium, 8:30am to 7pm at The Starr Center (185 Cambridge Street, Boston, MA). This is an excellent networking opportunity, especially for those based in the Boston area. Register here.
  • [NEW] 13 Dec 2018 (online): CDD webinar entitled “New Strategies in Antibiotic Drug Development.” Register here.
  • 15 Jan 2018 (London): BSAC’s Antimicrobial Chemotherapy Conference 2019: “An ABC for everyone involved in developing new antimicrobials.” Details here.
  • 14-15 Mar 2019 (Berlin): BEAM– and ND4BB-ENABLE-sponsored Berlin Conference on Novel Antimicrobials and AMR Diagnostics. Details here.
  • 21-22 Mar 2019 (Birmingham, UK): BSAC Spring Conference.
  • 19-27 Oct 2019 (Annecy, France): International Course on Antibiotics and Resistance (ICARe) – A soup-to-nuts intensive residential training program on all things AMR, especially R&D for new antibiotics. See this link for details.

Share

How the sausage is made: A day of advocacy for PASTEUR

Dear All, Along with more than 50 others, I spent Tuesday 12 Sep 2023 on Capitol Hill visiting offices of members of Congress (Senate and House) seeking support for the PASTEUR Act. If you’re a regular reader, you’ll know that we now have substantial bipartisan support for PASTEUR: it was re-introduced as The Pioneering Antimicrobial

Canada says, “Let’s pull together!” in a major new report

Dear All (and with thanks to Kevin for co-authoring): Yesterday saw the release of a major new report on Pull incentives from Canada! The report’s cover art eloquently summarizes its key message: Well said … and proves that a picture really is worth 1,000 words! Here are the links you’ll need: The report’s webpage at the

€100m HERA Invest fund; Sign to support PASTEUR; Superb AMR movie!

Dear All,  Expanding the available Push funding, the EU’s HERA (Health Emergency Preparedness and Response Authority) has created HERA Invest by allocating €100m in support early and late phases of clinical trials. HERA Invest is open on a rolling application basis to EU-based SMEs developing medical countermeasures that address one of the following cross-border health threats: (i)

Scroll to Top